NL2037729A - Preparation and applications of temperature-sensitive drug-loading composite nanoparticles - Google Patents
Preparation and applications of temperature-sensitive drug-loading composite nanoparticles Download PDFInfo
- Publication number
- NL2037729A NL2037729A NL2037729A NL2037729A NL2037729A NL 2037729 A NL2037729 A NL 2037729A NL 2037729 A NL2037729 A NL 2037729A NL 2037729 A NL2037729 A NL 2037729A NL 2037729 A NL2037729 A NL 2037729A
- Authority
- NL
- Netherlands
- Prior art keywords
- composite nanoparticles
- hbcos
- drug
- preparation
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 105
- 239000002131 composite material Substances 0.000 title claims abstract description 102
- 238000011068 loading method Methods 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims abstract description 17
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940071162 caseinate Drugs 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- -1 Hydroxybutyl Chemical group 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 229940080237 sodium caseinate Drugs 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 abstract description 6
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 230000009881 electrostatic interaction Effects 0.000 description 7
- 239000002539 nanocarrier Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001977 poly(N,N-diethylacrylamides) Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000004984 smart glass Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Werkwijze voor het bereiden van temperatuurgevoelige samenge- stelde nanodeeltjes, waarin de nanodeeltjes bestaan uit Hydroxybu- tyl Chitosan (HBCOS) en Natrium Caseinaat (CN), en wordt specifiek bereid door de volgende werkwijze: (1) respectievelijk oplossen van de CN en de HBCOS in water, men- gen van de CN en de HBCOS om een massaverhouding van de CN tot de HBCOS van 1:0,4-0,8 te verkrijgen, regelen van de pH, en vormen van de samengestelde nanodeeltjes; en (2) genipine toe te voegen, gedurende 24-72 uur bij 35°C-39°C te reageren, de pH te regelen, dan gedurende 1-2 dagen te dialyseren en vervolgens te vriesdrogen om vernette samengestelde nanodeel- tjes te verkrijgen.
2. Bereidingswijze volgens conclusie 1, waarbij in stap 2) de con- centratie van de CN 0,5~1,5 mg/mL is, de concentratie van de HBCOS 30-50 mg/mL is en een gewichtsverhouding van de CN tot de HBCOS 1:0,4~0,8 is; een pH-waarde 5,8-6,5 is.
3. Bereidingswijze volgens conclusie 1 of 2, waarbij de concentra- tie van de genipine toegevoegd in stap 2) 0,01-0,1 mg/mL is, en een pH-waarde van 7,0-7,8.
4. Bereidingswijze van geneesmiddelbeladende samengestelde nano- deeltjes, die op de volgende manier worden bereid: 1) respectievelijk oplossen van de CN en de HBCOS in water, mengen van de CN en de HBCOS om een massaverhouding van de CN tot de HBCOS te verkrijgen van 1:0,4-0,8, regelen van de pH, en vormen van de samengestelde nanodeeltjes; en 2) genipine toe te voegen, gedurende 24-72 uur bij 35°C-39°C te re- ageren, de pH te regelen, dan gedurende 1-2 dagen te dialyseren en vervolgens te vriesdrogen om vernette samengestelde nanodeeltjes te verkrijgen 3) de in stap (2) bereide samengestelde nanodeeltjes opnieuw op- lossen met ultrazuiver water, de pH regelen, een geneesmiddel toe-
voegen, 12-15 uur schudden bij kamertemperatuur in het donker, dan dialyseren met ultrazuiver water en het dialysaat elke 8-15 uur verversen; en vriesdrogen op een monster in een dialysezak om de geneesmiddelbeladen samengestelde nanodeeltjes te verkrijgen.
5. Bereidingswijze volgens conclusie 4, waarin de concentratie van de CN 0,5~1,5 mg/mL is, de concentratie van de HBCOS 30-50 mg/mL is en een gewichtsverhouding van de CN tot de HBCOS 1:0,4~0,8 is; een pH-waarde 5,8-6,5 is.
6. Bereidingswijze volgens conclusie 4 of 5, waarbij de concentra- tie van de genipine toegevoegd in stap 2) 0,01-0,1 mg/mL is, en een pH-waarde 7,0-7,8.
7. Bereidingswijze volgens conclusie 6, waarin een eindconcentra- tie van de samengestelde nanodeeltjes opgelost in stap 3) 0,8~1,2 mg/mL is; en het geneesmiddel een chemisch geneesmiddel is.
8. Temperatuurgevoelige samengestelde nanodeeltjes verkregen door de bereidingswijze volgens een van de conclusies 1 tot en met 3.
9. Medicijnbelastende samengestelde nanodeeltjes verkregen door de bereidingswijze volgens een van de conclusies 4 tot en met 7.
10. Toepassingen van de werkwijze volgens een van de conclusies 1 tot en met 3, de werkwijze volgens een van de conclusies 4 tot en met 7, de temperatuurgevoelige samengestelde nanodeeltjes volgens conclusie 8, of de geneesmiddelbeladende samengestelde nanodeel- tjes volgens conclusie 9 bij de bereiding van geneesmiddelen voor de behandeling van tumoren.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310583091.5A CN116459232B (zh) | 2023-05-23 | 2023-05-23 | 一种温敏载药复合纳米颗粒的制备及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2037729A true NL2037729A (en) | 2024-06-11 |
Family
ID=87173839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2037729A NL2037729A (en) | 2023-05-23 | 2024-05-21 | Preparation and applications of temperature-sensitive drug-loading composite nanoparticles |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116459232B (nl) |
| NL (1) | NL2037729A (nl) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284884B (zh) * | 2008-02-19 | 2013-12-25 | 上海其胜生物制剂有限公司 | 一种温敏性壳聚糖衍生物-羟丁基壳聚糖的制备方法 |
| CN103494775A (zh) * | 2013-09-17 | 2014-01-08 | 南昌大学 | 京尼平交联壳聚糖载药微球的制备方法 |
| CN103705938A (zh) * | 2013-12-26 | 2014-04-09 | 南京农业大学 | 一种耐胃酸的多肽-多糖纳米颗粒及其制备方法 |
| CN105381472B (zh) * | 2015-12-08 | 2018-12-07 | 华南农业大学 | 月见草素b-酪蛋白磷酸肽-壳聚糖纳米粒及制备方法与应用 |
| CN108310460B (zh) * | 2018-02-02 | 2021-08-03 | 武汉大学 | 可注射高强度温敏性改性甲壳素基水凝胶及其制备方法和应用 |
| CN112159533A (zh) * | 2020-09-24 | 2021-01-01 | 长春工业大学 | 一种酪蛋白酸钠/羧甲基壳聚糖导电粘韧水凝胶及其制备方法 |
| CN113230234B (zh) * | 2021-04-27 | 2022-04-26 | 江苏大学 | 负载生物活性成分的蛋白肽-多糖纳米颗粒的超声波制备方法 |
| CN114868916B (zh) * | 2022-03-18 | 2023-07-25 | 江南大学 | 姜黄素/抗坏血酸稳定化核-壳粒子及其制备方法 |
-
2023
- 2023-05-23 CN CN202310583091.5A patent/CN116459232B/zh active Active
-
2024
- 2024-05-21 NL NL2037729A patent/NL2037729A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116459232A (zh) | 2023-07-21 |
| CN116459232B (zh) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting ability and reducing adverse side effects | |
| Jain et al. | Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery | |
| Zhou et al. | Redox-and MMP-2-sensitive drug delivery nanoparticles based on gelatin and albumin for tumor targeted delivery of paclitaxel | |
| Deng et al. | Green preparation process, characterization and antitumor effects of doxorubicin–BSA–dextran nanoparticles | |
| Wang et al. | Bromelain-immobilized and lactobionic acid-modified chitosan nanoparticles for enhanced drug penetration in tumor tissues | |
| Gao et al. | A smart drug delivery system responsive to pH/enzyme stimuli based on hydrophobic modified sodium alginate | |
| Chen et al. | Saporin-loaded CD44 and EGFR dual-targeted nanogels for potent inhibition of metastatic breast cancer in vivo | |
| US9522114B1 (en) | Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin | |
| Zhao et al. | Polydopamine-based surface modification of paclitaxel nanoparticles for osteosarcoma targeted therapy | |
| Zhang et al. | Bio-inspired keratin-based core-crosslinked micelles for pH and reduction dual-responsive triggered DOX delivery | |
| AU2018262962B2 (en) | Immunomagnetic nanocapsule, fabrication method and use thereof, and kit for treating cancer | |
| Barthold et al. | Preparation of nanosized coacervates of positive and negative starch derivatives intended for pulmonary delivery of proteins | |
| US10765745B2 (en) | Multifunctional nanoparticle systems and methods for cancer diagnosis and combination therapy | |
| Matha et al. | Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery | |
| Zhang et al. | pH-Activated surface charge-reversal double-crosslinked hyaluronic acid nanogels with feather keratin as multifunctional crosslinker for tumor-targeting DOX delivery | |
| Vasi et al. | Poly (acrylic acid)–poly (ethylene glycol) nanoparticles designed for ophthalmic drug delivery | |
| Hellmers et al. | Characterization and in vitro cytotoxicity of doxorubicin-loaded γ-polyglutamic acid-chitosan composite nanoparticles | |
| Catarata et al. | Controlled drug release from polyelectrolyte–drug conjugate nanoparticles | |
| Nultsch et al. | Matrix metalloprotease triggered bioresponsive drug delivery systems–design, synthesis and application | |
| Callari et al. | Drug induced self-assembly of triblock copolymers into polymersomes for the synergistic dual-drug delivery of platinum drugs and paclitaxel | |
| Zhang et al. | Effects of nanoparticle-mediated Co-delivery of bFGF and VEGFA genes to deep burn wounds: An in vivo study | |
| Hong et al. | Dual disassembly and biological evaluation of enzyme/oxidation-responsive polyester-based nanoparticulates for tumor-targeting delivery | |
| Shargh et al. | Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy | |
| Clegg et al. | Peptide conjugation enhances the cellular co-localization, but not endosomal escape, of modular poly (acrylamide-co-methacrylic acid) nanogels | |
| EP2474306A1 (en) | Particle composition and medicinal composition comprising same |